Aurora Cannabis (ACB) Short-Term Debt repayments (2017 - 2023)
Aurora Cannabis (ACB) reported Short-Term Debt repayments of -$1.0 million for Q4 2023, down 26.23% year-over-year from -$1.4 million in Q4 2022, and down 170.61% quarter-over-quarter from -$384900.1 in Q3 2023.
Aurora Cannabis (ACB) Short-Term Debt repayments (2017 - 2023) Analysis & Trends
Aurora Cannabis (ACB) has 7 years of Short-Term Debt repayments data on file, last reported at -$1.0 million in Q4 2023.
- Short-Term Debt repayments for Q4 2023 came in at -$1.0 million, down 26.23% year-over-year; the trailing twelve-month figure through Dec 2023 was -$2.8 million (up 59.33% YoY), and the FY2023 annual result was -$384137.5, changed N/A from the prior year.
- Short-Term Debt repayments fell to -$1.0 million in Q4 2023 per ACB's latest filing, from -$384900.1 in the prior quarter.
- Over five years, Short-Term Debt repayments peaked at $1.6 million in Q1 2019 and troughed at -$73.7 million in Q2 2020.
- A 5-year average of -$7.7 million and a median of -$1.6 million in 2023 frame the typical range for Short-Term Debt repayments.
- The sharpest annual moves came in 2019 and 2020: Short-Term Debt repayments jumped 1004.16% in 2019, then tumbled 156442.24% in 2020.
- A 5-year view of Short-Term Debt repayments shows it stood at -$2.7 million in 2019, then slumped by 79.59% to -$4.8 million in 2020, then jumped by 88.38% to -$556880.9 in 2021, then plunged by 48.17% to -$825107.3 in 2022, then slipped by 26.23% to -$1.0 million in 2023.
- Business Quant data shows ACB's Short-Term Debt repayments at -$1.0 million in Q4 2023, -$384900.1 in Q3 2023, and -$825107.3 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | -384,900.12 |
| Sep 30, 2023 | -384,900.12 |
| Dec 31, 2022 | -825,107.29 |
| Dec 31, 2022 | -825,107.29 |
| Sep 30, 2022 | -537,489.12 |
| Sep 30, 2022 | -537,489.12 |
| Sep 30, 2021 | -556,880.93 |
| Sep 30, 2021 | -556,880.93 |
| Mar 31, 2021 | -4.94 Mn |
| Mar 31, 2021 | -4.94 Mn |
| Dec 31, 2020 | -4.79 Mn |
| Dec 31, 2020 | -4.79 Mn |
| Sep 30, 2020 | -12.23 Mn |
| Sep 30, 2020 | -12.23 Mn |
| Jun 30, 2020 | -73.71 Mn |
| Jun 30, 2020 | -73.71 Mn |
| Mar 31, 2020 | -4.80 Mn |
| Mar 31, 2020 | -4.80 Mn |